ATTO — Attovia Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2058707 ·
Last close
$14.86
Market Cap
$679.29M
52W High
$28.00
52W Low
$12.94
ADV30
321,060
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -25,024,000 | -22,271,000 | 411,824,000 | 115,366,000 | 14,083,000 |
| Jun 2026 | 450,000 | — | -21,803,000 | -20,687,000 | 128,348,000 | 32,829,000 | 273,807,000 |
| Mar 2026 | 0 | — | -19,955,000 | -18,656,000 | 146,086,000 | 43,297,000 | 271,601,000 |
| Dec 2025 | 990,000 | — | -18,833,000 | -17,258,000 | 165,893,000 | 40,193,000 | 273,329,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,946,000
Investing CF
$-162,646,000
Financing CF
$306,193,000
CapEx
$-430,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.51
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-172,624,000
Inventory
—
Receivables
$700,000
ST Investments
$280,573,000
EBIT TTM
$-85,615,000
Pretax Income TTM
$-78,872,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,800,000
EBITDA
$-75,251,000
Free Cash Flow
—
Enterprise Value
$876,014,144
Total Cash
$115,132,000
Total Debt
$4,326,000
Shares Out
45,712,536
Trailing EPS
$-5.53
Book Value
$-24.27
ROE
—
ROA
—
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,350,000 | -67,159,000 | -60,627,000 | 165,893,000 | 273,329,000 | -107,436,000 | -59,199,000 |
| Dec 2024 | 0 | -41,553,000 | -39,801,000 | 76,716,000 | 123,541,000 | -46,825,000 | -35,035,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$128,348,000
Forward EPS
$-2.39
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IAM | Iambic Therapeutics, Inc. | $674.04M | $14.22 | — |
| SLDB | Solid Biosciences Inc. | $695.33M | $6.23 | — |
| DBVT | DBV Technologies S.A. | $627.78M | $9.99 | — |
| AURA | Aura Biosciences, Inc. | $744.13M | $7.15 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $608.33M | $10.79 | — |
News headlines (Yahoo Finance, 1h cache)
Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
2026-11-09 21:05 · Yahoo
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials
2026-11-06 11:14 · Yahoo
Attovia Therapeutics Announces Positive Topline 12-Week Results from Phase 1b Study of ATTO-1310 in Patients with Chronic Pruritus and High-Itch Atopic Dermatitis
2026-11-05 21:05 · Yahoo
Attovia Therapeutics to Participate in Upcoming Investor Conferences
2026-10-27 20:05 · Yahoo
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026
2026-09-28 20:05 · Yahoo
Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits
2026-09-22 03:25 · Yahoo
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
2026-09-02 20:05 · Yahoo
Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says
2026-08-31 15:16 · Yahoo
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
2026-09-22 17:39 · Yahoo
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
2026-08-31 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.